Arvinas Licenses Global Rights for VEPPANU to Rigel for $85M Upfront, up to $320M Milestones

summarizeSummary

Arvinas has entered a global licensing agreement with Rigel Pharmaceuticals for its FDA-approved drug VEPPANU, securing $85 million in upfront and transition payments, plus potential milestones and royalties.

check_boxKey Events

• Global Licensing Deal for VEPPANU

  Arvinas and Pfizer have licensed exclusive global development, manufacturing, and commercialization rights for VEPPANU (vepdegestrant) to Rigel Pharmaceuticals, Inc.

• Significant Upfront and Transition Payments

  Arvinas will receive $42.5 million in immediate cash ($35 million upfront and $7.5 million upon successful completion of transition activities) from the total $85 million paid by Rigel, split evenly with Pfizer.

• Potential Future Milestones and Royalties

  Arvinas is eligible for up to an additional $160 million in development, regulatory, and commercial milestone payments, plus tiered royalties in the mid-teens to mid-20s on worldwide net sales (Arvinas's share).

• Strategic Focus on Pipeline and Cash Runway

  This agreement allows Arvinas to reduce commercialization risk for VEPPANU and invest in its early-stage pipeline, aligning with its stated goal of maintaining a strong cash runway.

auto_awesomeAnalysis

This agreement provides Arvinas with a substantial immediate cash infusion and future revenue streams from its recently FDA-approved drug, VEPPANU, while transferring commercialization responsibilities and risks to Rigel. This strategic move allows Arvinas to strengthen its balance sheet and focus resources on its early-stage pipeline, extending its cash runway.